Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

TOKYO & HAYWARD, Calif.–(BUSINESS WIRE)–Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This … [Read more…]

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026 Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical … [Read more…]

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60 … [Read more…]

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

First presentation of clinical data from the sixth DXd antibody drug conjugate from the oncology pipeline of Daiichi Sankyo Early results support continued development of DS-3939, a potential first-in-class TA-MUC1 directed antibody drug conjugate TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated … [Read more…]

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

AstraZeneca and Daiichi Sankyo’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death in TROPION-Breast02 DATROWAY is the first and only therapy to significantly improve overall survival vs. chemotherapy in this patient population WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the TROPION-Breast02 Phase III trial showed … [Read more…]

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

Daiichi Sankyo and AstraZeneca’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive results from the TROPION-Breast02 phase 3 trial … [Read more…]

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Conference Call October 20, 8:45am EST QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT … [Read more…]

Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months

Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–#AAO2025—Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the … [Read more…]

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology Congress 2025 With these results, KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show statistically … [Read more…]